Your browser doesn't support javascript.
loading
Genetic and pharmaceutical targeting of HIF1α allows combo-immunotherapy to boost graft vs. leukemia without exacerbation graft vs. host disease.
Bailey, Christopher; Wei, Yuanyi; Yan, Jinsong; Huang, Dan; Zhang, Peng; Qi, Chong; Lazarski, Christopher; Su, JuanJuan; Tang, Fei; Wong, Chun-Shu; Zheng, Pan; Liu, Yan; Liu, Yang; Wang, Yin.
Afiliación
  • Bailey C; Division of Immunotherapy, Institute of Human Virology, Department of Surgery and Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • Wei Y; Division of Immunotherapy, Institute of Human Virology, Department of Surgery and Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • Yan J; Department of Hematology, The Second Hospital of Dalian Medical University, Dalian, China.
  • Huang D; Department of Hematology, The Second Hospital of Dalian Medical University, Dalian, China.
  • Zhang P; Department of Neurosurgery, Beijing Children's Hospital, Capital Medical University, National Cancer for Children's Health, Beijing, China.
  • Qi C; Institute of Translational Medicine, The First Hospital, Jilin University, Changchun, Jilin 130061, China.
  • Lazarski C; Center for Cancer and Immunology Research, Children's Research Institute, Washington, DC 20010, USA.
  • Su J; Division of Immunotherapy, Institute of Human Virology, Department of Surgery and Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • Tang F; Division of Immunotherapy, Institute of Human Virology, Department of Surgery and Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • Wong CS; Center for Cancer and Immunology Research, Children's Research Institute, Washington, DC 20010, USA.
  • Zheng P; Division of Immunotherapy, Institute of Human Virology, Department of Surgery and Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA; OncoC4, Inc., Rockville, MD 20852, USA.
  • Liu Y; Division of Immunotherapy, Institute of Human Virology, Department of Surgery and Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Electronic address: yanliu@ihv.umaryland.edu.
  • Liu Y; Division of Immunotherapy, Institute of Human Virology, Department of Surgery and Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA; OncoC4, Inc., Rockville, MD 20852, USA. Electronic address: yangl@oncoc4.com.
  • Wang Y; Division of Immunotherapy, Institute of Human Virology, Department of Surgery and Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Electronic address: yin.wang@ihv.umaryland.edu.
Cell Rep Med ; 4(11): 101236, 2023 11 21.
Article en En | MEDLINE | ID: mdl-37827154
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia / Enfermedad Injerto contra Huésped Límite: Animals / Humans Idioma: En Revista: Cell Rep Med Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia / Enfermedad Injerto contra Huésped Límite: Animals / Humans Idioma: En Revista: Cell Rep Med Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos